Literature DB >> 33658043

Characterization of polycystic ovary syndrome among Flo app users around the world.

Tarun Jain1,2, Olivia Negris3, Dannielle Brown3, Isabel Galic3, Rodion Salimgaraev4, Liudmila Zhaunova4.   

Abstract

BACKGROUND: Polycystic ovary syndrome (PCOS) is a complex and multi-faceted endocrine disorder that affects 5-20% of women. Literature is limited regarding potentially differing PCOS phenotypes among women around the world.
OBJECTIVE: To use Flo app technology to understand the multifaceted characteristics of PCOS across several countries and identify contributing risk factors to the development of this condition. STUDY
DESIGN: Flo is a widely used female health and wellbeing app with period tracking functionality that provides a globally representative and medically unbiased perspective on PCOS symptomatology. A chatbot dialog on PCOS was subsequently administered on the Flo application (app) to users from 142 countries (with at least 100 respondents) who have the app running in English during September-October 2019.
RESULTS: For analyses, we selected the five countries with the greatest number of respondents: US (n = 243,238), UK (n = 68,325), India (n = 40,092), Philippines (n = 35,131), and Australia (n = 29,926). Bloating was the most frequently reported symptom among PCOS-positive women and appeared to be the main predictor of PCOS in our model (odds ratio 3·76 [95% CI 3·60-3·94]; p < 0·0001). Additional top predictors of PCOS are high blood cholesterol and glucose levels. As BMI increased, the percentage of women who reported a physician-confirmed PCOS diagnosis also increased. However, women in India did not follow this trend.
CONCLUSION: Our findings are based on the largest known PCOS dataset and indicate that symptoms are more complex than previously understood. The most frequently reported symptoms (bloating, facial hirsutism, irregular cycles, hyperpigmentation, and baldness) are broader than those included in the Rotterdam criteria. Future work should reevaluate and refine the criteria utilized in PCOS diagnosis.

Entities:  

Keywords:  BMI; Bloating; Hirsutism; Menstrual cycle tracking; Polycystic ovary syndrome

Year:  2021        PMID: 33658043      PMCID: PMC7927251          DOI: 10.1186/s12958-021-00719-y

Source DB:  PubMed          Journal:  Reprod Biol Endocrinol        ISSN: 1477-7827            Impact factor:   5.211


  41 in total

1.  Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study.

Authors:  Sarah Wild; Tracey Pierpoint; Howard Jacobs; Paul McKeigue
Journal:  Hum Fertil (Camb)       Date:  2000       Impact factor: 2.767

2.  Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases.

Authors:  D S Kiddy; P S Sharp; D M White; M F Scanlon; H D Mason; C S Bray; D W Polson; M J Reed; S Franks
Journal:  Clin Endocrinol (Oxf)       Date:  1990-02       Impact factor: 3.478

Review 3.  Ethnic differences in the phenotypic expression of polycystic ovary syndrome.

Authors:  Yue Zhao; Jie Qiao
Journal:  Steroids       Date:  2013-04-25       Impact factor: 2.668

4.  Obesity is the predominant predictor of impaired glucose tolerance and metabolic disturbance in polycystic ovary syndrome.

Authors:  So-Jung Liang; Tsan-Hon Liou; Hui-Wen Lin; Chun-Sen Hsu; Chii-Ruey Tzeng; Ming-I Hsu
Journal:  Acta Obstet Gynecol Scand       Date:  2012-08-13       Impact factor: 3.636

5.  Overweight and obesity in Australia: the 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab).

Authors:  Adrian J Cameron; Timothy A Welborn; Paul Z Zimmet; David W Dunstan; Neville Owen; Jo Salmon; Marita Dalton; Damien Jolley; Jonathan E Shaw
Journal:  Med J Aust       Date:  2003-05-05       Impact factor: 7.738

Review 6.  Role of obesity and adiposity in polycystic ovary syndrome.

Authors:  E Diamanti-Kandarakis
Journal:  Int J Obes (Lond)       Date:  2007-11       Impact factor: 5.095

7.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.

Authors: 
Journal:  Fertil Steril       Date:  2004-01       Impact factor: 7.329

8.  Trend in obesity prevalence in European adult cohort populations during follow-up since 1996 and their predictions to 2015.

Authors:  Anne von Ruesten; Annika Steffen; Anna Floegel; Daphne L van der A; Giovanna Masala; Anne Tjønneland; Jytte Halkjaer; Domenico Palli; Nicholas J Wareham; Ruth J F Loos; Thorkild I A Sørensen; Heiner Boeing
Journal:  PLoS One       Date:  2011-11-10       Impact factor: 3.240

Review 9.  Geographical Prevalence of Polycystic Ovary Syndrome as Determined by Region and Race/Ethnicity.

Authors:  Wendy M Wolf; Rachel A Wattick; Olivia N Kinkade; Melissa D Olfert
Journal:  Int J Environ Res Public Health       Date:  2018-11-20       Impact factor: 3.390

10.  Polycystic ovary syndrome patients with high BMI tend to have functional disorders of androgen excess: a prospective study.

Authors:  Chun Yuan; Xiaoqiang Liu; Yundong Mao; Feiyang Diao; Yugui Cui; Jiayin Liu
Journal:  J Biomed Res       Date:  2016-04-30
View more
  1 in total

1.  Metformin Improves the Hepatic Steatosis Index in Non-Obese Patients with Polycystic Ovary Syndrome.

Authors:  Annika Riemann; Martina Blaschke; Annukka Jauho-Ghadimi; Heide Siggelkow; Katja Susanne Claudia Gollisch
Journal:  J Clin Med       Date:  2022-07-24       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.